Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert

Experimental in-vitro high speed camera analysis of femtosecond laser pattern application

Search Title by author or title

Session Details

Session Title: Moderated Poster Session: FLACS

Session Date/Time: Sunday 11/09/2016 | 14:00-15:00

Paper Time: 14:30

Venue: Poster Village: Pod 1

First Author: : F.Kretz GERMANY

Co Author(s): :    G. Auffarth              

Abstract Details


To evaluate Femtosecond-Laser (Fs) assissted cataract surgery (FLACS) lens fragmentation pattern with the LENSAR Fs-Laser in an in vitro model using a high speed camera.


David J. Apple International Laboratory for Ocular Pathology, Department of Ophthalmology, University of Heidelberg, Heidelberg, Germany


The LENSAR Femtosecond cataract laser system (LENSAR, LLC) is a combination of a Femtosecond laser with a Scheimpflug-based diagnostic system. We used a special hydrogel based material with high water content with a lens shaped form to visualize Fs-Laser application pattern in the material. A high speed camera (AOS Technologies, Inc.) with a 1.3 M Pixel resolution for 5000 frames per second (fps), 900x700 Pixel resolution for 20.000 fps and 300x320 Pixel resolution for 100.000fps was used.


Different fragmentation and capsulotomy patterns and energy levels were recorded. With this model the effect of the LENSAR FS-Laser pattern could be visualized and displayed.


The poster displays results and video-footage of the high speed camera analysis of application pattern of the LENSAR Fs-Laser in a new in vitro model.

Financial Disclosure:

One or more of the authors receives consulting fees, retainer, or contract payments from a competing company, One or more of the authors travel has been funded, fully or partially, by a competing company, One or more of the authors research is funded, fully or partially, by a competing company, One or more of the authors receives non-monetary benefits from a competing company.

Back to previous